weaker vol off-set drug cost benefit
dmg sale track
quarter roughli line guidanc maintain
report adj ep consensus/our estimate line item
adjust oper incom roughli line consensu actual slightli
better dva intern expect like confus lighter
volum off-set greater benefit lower calcimimet price ad
y/i despit rel larg benefit maintain guidanc
appear guidanc includ much increment benefit
calcimimet year vs previou guidanc guidanc alreadi includ impact
shift could turn y/i headwind result view core dialysi
result larg in-lin posit made strong comment davita medic
group dmg sale move toward close lower
estim reflect slower top line outlook maintain oper incom
margin est shown abil manag cost reaffirm buy see
potenti upsid signific capit catalyst dmg sale close
dmg sale track close
see clear path get dmg sale approv ftc sinc
comment posit sale three week ago increment progress made
addit dmg result solid
volum lt rang impact competit
store treatment growth deceler
total treatment estimate/consensu continu see pressur
increas avail kidney transplant ad also see
competitor ramp denovo howev compani feel well posit
compet given scale dialysi price est/consensu although
payor mix improv slightli q/q ancillary/intern revenue estimate total
revenu estimate/consensu
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
davita inc lead dialysi provid
unit state compani oper
outpati clinic us serv
patient also oper countri
outsid us
sale davita medic group dmg
posit use bulk proce
share repurchas still pay debt
make increment invest
health care servic outsid dialysi
po base ebitda estim around high end
stand-alon histor rang ebitda dmg sale allow
focu core dialysi busi deploy capit
upsid risk po commerci mix better expect
reimburs better expect make chang third
downsid risk po commerci price pressur could continu
potenti commerci mix pressur manag care vast major dialysi
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
